Los Angeles Capital Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.3K | Sell |
440
-99
| -18% | -$5.98K | ﹤0.01% | 1567 |
|
|
2026
Q1 | $21.7K | Sell |
539
-40,958
| -99% | -$1.53M | ﹤0.01% | 1719 |
|
|
2025
Q4 | $3M | Sell |
41,497
-35,583
| -46% | -$2.79M | 0.01% | 372 |
|
|
2025
Q3 | $6.41M | Buy |
77,080
+72,380
| +1,540% | +$5.24M | 0.02% | 309 |
|
|
2025
Q2 | $345K | Sell |
4,700
-44,604
| -90% | -$3.23M | ﹤0.01% | 1001 |
|
|
2025
Q1 | $5.63M | Buy |
49,304
+22,791
| +86% | +$1.39M | 0.02% | 276 |
|
|
2024
Q4 | $1.34M | Hold |
26,513
| – | – | 0.01% | 543 |
|
|
2024
Q3 | $1.23M | Hold |
26,513
| – | – | 0.01% | 581 |
|
|
2024
Q2 | $861K | Sell |
26,513
-22,306
| -46% | -$611K | ﹤0.01% | 699 |
|
|
2024
Q1 | $1.23M | Sell |
48,819
-1,400
| -3% | -$33.1K | ﹤0.01% | 630 |
|
|
2023
Q4 | $1.63M | Sell |
50,219
-9,072
| -15% | -$249K | 0.01% | 522 |
|
|
2023
Q3 | $1.62M | Buy |
59,291
+47,359
| +397% | +$1.37M | 0.01% | 503 |
|
|
2023
Q2 | $265K | Buy |
11,932
+2,037
| +21% | +$46.9K | ﹤0.01% | 1042 |
|
|
2023
Q1 | $214K | Sell |
9,895
-48,101
| -83% | -$1.05M | ﹤0.01% | 1109 |
|
|
2022
Q4 | $1.18M | Sell |
57,996
-5,000
| -8% | -$125K | 0.01% | 654 |
|
|
2022
Q3 | $1.61M | Buy |
62,996
+29,214
| +86% | +$782K | 0.01% | 556 |
|
|
2022
Q2 | $803K | Buy |
33,782
+20,360
| +152% | +$444K | ﹤0.01% | 799 |
|
|
2022
Q1 | $302K | Buy |
+13,422
| New | +$286K | ﹤0.01% | 1234 |
|
|
2021
Q2 | – | Sell |
-8,615
| Closed | -$205K | – | 1555 |
|
|
2021
Q1 | $205K | Sell |
8,615
-6,585
| -43% | -$176K | ﹤0.01% | 1535 |
|
|
2020
Q4 | $398K | Sell |
15,200
-15,620
| -51% | -$329K | ﹤0.01% | 1287 |
|
|
2020
Q3 | $536K | Sell |
30,820
-7,510
| -20% | -$120K | ﹤0.01% | 1053 |
|
|
2020
Q2 | $645K | Buy |
38,330
+20,600
| +116% | +$289K | ﹤0.01% | 1013 |
|
|
2020
Q1 | $211K | Buy |
17,730
+2,830
| +19% | +$35K | ﹤0.01% | 1158 |
|
|
2019
Q4 | $180K | Buy |
+14,900
| New | +$207K | ﹤0.01% | 1214 |
|
|
2019
Q1 | – | Sell |
-12,893
| Closed | -$172K | – | 1368 |
|
|
2018
Q4 | $172K | Sell |
12,893
-95,994
| -88% | -$1.27M | ﹤0.01% | 1215 |
|
|
2018
Q3 | $1.53M | Buy |
108,887
+49,345
| +83% | +$690K | 0.01% | 742 |
|
|
2018
Q2 | $936K | Sell |
59,542
-17,340
| -23% | -$302K | 0.01% | 924 |
|
|
2018
Q1 | $1.26M | Sell |
76,882
-72,960
| -49% | -$1.35M | 0.01% | 759 |
|
|
2017
Q4 | $2.71M | Buy |
149,842
+79,793
| +114% | +$1.45M | 0.01% | 583 |
|
|
2017
Q3 | $1.35M | Buy |
70,049
+54,460
| +349% | +$812K | 0.01% | 720 |
|
|
2017
Q2 | $184K | Buy |
+15,589
| New | +$169K | ﹤0.01% | 1158 |
|
Other funds holding CORT
ISL
PA
Los Angeles Capital Management's CORT Position: Q2 2026 in Review
Los Angeles Capital Management reduced its Corcept Therapeutics (CORT) stake by 18% in Q2 2026, selling an estimated $5.98K and leaving 440 shares worth $38.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.
Los Angeles Capital Management first reported a position in CORT in Q2 2017 and has held it in 31 quarters since. The position peaked at $6.41M in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- Los Angeles Capital Management held 440 shares of Corcept Therapeutics worth $38.3K as of Q2 2026.
- Los Angeles Capital Management sold 99 Corcept Therapeutics shares in Q2 2026, an estimated $5.98K.
- Corcept Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1567 holding.
- Los Angeles Capital Management first reported a position in Corcept Therapeutics in Q2 2017 and has held it in 31 quarters since.
- Los Angeles Capital Management's Corcept Therapeutics position peaked at $6.41M in Q3 2025.
- 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.